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USP2a alters chemotherapeutic response by
modulating redox
B Benassi*,1, M Marani2, M Loda3,4 and G Blandino5
Cancer cells are characterized by altered ubiquitination of many proteins. The ubiquitin-specific protease 2a (USP2a) is a
deubiquitinating enzyme overexpressed in prostate adenocarcinomas, where it exhibits oncogenic behavior in a variety of ways
including targeting c-Myc via the miR-34b/c cluster. Here we demonstrate that USP2a induces drug resistance in both
immortalized and transformed prostate cells. Specifically, it confers resistance to typically pro-oxidant agents, such as cisplatin
(CDDP) and doxorubicin (Doxo), and to taxanes. USP2a overexpression protects from drug-induced oxidative stress by reducing
reactive oxygen species (ROS) production and stabilizing the mitochondrial membrane potential (DW), thus impairing
downstream p38 activation and triggering of apoptosis. The molecular mediator of the USP2a protective function is the
glutathione (GSH). Through miR-34b/c-driven c-Myc regulation, USP2a increases intracellular GSH content, thus interfering with
the oxidative cascade triggered by chemotherapeutic agents. In light of these findings, targeting Myc and/or miR-34b/c might
revert chemo-resistance.
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Deubiquitinating enzymes (DUBs) represent one of the largest
families of proteins responsible for regulating the ubiquitin–
proteasome system by opposing ubiquitination.1 Although
DUBs have been first identified for their role in protein
stabilization, in recent years several other mechanisms have
emerged by which the balance ubiquitination/deubiquitination
can regulate protein level, activity and subcellular location, thus
driving different cellular processes from gene transcription and
DNA repair to cell cycle and apoptosis.2
Alteration in the ubiquitination pattern is observed in most
cancer cells, where it is manifested by destabilization of tumor
suppressors and activation of oncogenes. This justifies the
efforts for developing proteasome inhibitors in cancer therapy,
like Bortezomib used successfully in myeloma, neuroblas-
toma and mesothelioma therapy.3,4 DUB enzymes and
proteasome activity also affect cancer chemo- and radio-
resistance. In fact, proteasome inhibitors have been proposed
to be used in combination with conventional antineoplastic
agents. Therapeutic strategies are currently being investi-
gated to overcome chemo-resistance based on the mechan-
isms of ubiquitination/deubiquitination.5–9 However, despite
both the in vitro and in vivo (clinical) evidence of beneficial
antineoplastic effects, the reason why blocking proteasomal
degradation in a ‘non-specific’ manner results in differential
killing of tumor cell remains elusive.
In prostate, USP2a is a deubiquitinating enzyme specifically
overexpressed in about 40% of prostate adenocarcino-
mas.10,11 Its oncogenic behavior is ascribed to its interaction
with and prevention of proteosomal degradation of specific
protein targets involved in different cellular pathways, such as
fatty acid synthase (FASN), Mdm2, MdmX, AIF, Cyclin D,
Aurora-A and EGFR.12–18 Moreover, we recently reported that
USP2a is a master regulator of microRNA (miRNA or miR)
expression in both immortalized and transformed prostate
epithelial cells, where its overexpression specifically regulates
the miR-34b/c cluster to target c-Myc.19
miRNAs have been shown to be differently expressed in
benign compared with malignant prostate tissue and in
different stages of prostatic carcinogenesis.20–22 In addition,
certain miRs have been found to predict and affect sensitivity
to anticancer treatment.23 For instance, the tumor suppressor
miR-148a attenuates paclitaxel resistance in PC3 cells,24
while overexpression of miR-143 suppresses prostate pro-
liferation and migration, and increases sensitivity to docetaxel
(DTX) by targeting the EGFR/RAS/MAPK pathway.25 miR-34
family members in particular have been often associated to
cancer resistance. In prostate cancer, ectopic miR-34
expression triggers cell cycle arrest and growth inhibition
and attenuates chemo-resistance to camptothecin (CPT),
Doxo and paclitaxel exposure.26–28
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Here we demonstrate that USP2a modulates the suscept-
ibility to antineoplastic agents in prostate cells. In particular,
when overexpressed, USP2aWT is able to induce chemo-
resistance to typically pro-oxidant agents, such as CDDP and
Doxo, and also to the DTX taxane. The latter is in accordance
to that previously reported by our group, showing a marked
resistance to paclitaxel displayed by the USP2aWT prostate
cells if compared with EV (empty vector) and USP2aMUT
transfectants.11 In this regard, although taxanes are known to
be mainly mitotic inhibitors through disruption of microtubule
function, recent data on mitochondrial ROS formation showed
that they can trigger a direct mitochondrial damage, induce
mitochondrial permeability transition and ROS formation.29–31
Cisplatin in particular has been widely used in prostate
chemotherapy, along with mitoxanthrone and DTX.32 At
molecular level, it triggers apoptosis through oxidative stress,
p38 kinase activation and mitochondria impairment in different
cancer cell types, including prostate cells.33-36 In our experi-
mental model, we demonstrate for the first time that a specific
prostatic DUB, USP2a, protects from drug-induced oxidative
stress. The molecular mediator of the USP2a protective
function is the glutathione. Through miR-driven c-Myc
regulation, USP2a implements the intracellular glutathione
content by stimulating its synthesis, thus interfering with the
oxidative cascade triggered by the chemotherapeutic agents.
Results
USP2a overexpression confers resistance to pro-oxidant
agents to prostate cells. In a previously characterized
experimental model of human immortalized non-transformed
prostate epithelial cells (iPrEC), overexpressing either wild-type
(USP2aWT) or catalytically mutant USP2a (USP2aMUT),11,19
we evaluated the response to antineoplastic agents in terms
of both subG1 percentage and apoptotic PARP cleavage.
Figure 1 shows that the ectopic USP2aWT expression
(Figure 1a) significantly affects the response to different
drugs. Specifically, USP2aWT confers resistance to typically
pro-oxidant agents, such as cisplatin (Figure 1b) and
doxorubicin (Figure 1d), and to taxanes (docetaxel,
Figure 1c, and Priolo et al.11). The USP2a antiapoptotic
function seems to be related to its enzymatic activity, as the
dose-dependent effects reported for USP2aMUT resemble
those elicited by the empty vector clone. Also in a model of
transformed prostate cells (LNCaP cancer cell line), cells
acquire resistance to CDDP, DTX and Doxo upon ectopic
expression of USP2aWT (Supplementary Figure 1a) as the
percentage of both apoptotic cells and PARP cleavage levels
is significantly reduced in USP2aWT when compared with
control cells (Supplementary Figure 1b). Accordingly, USP2a
silencing (Supplementary Figure 1c) triggers a massive
increase of apoptosis in response to CDDP, DTX and Doxo
treatment, as demonstrated by the augmented subG1
percentage and downstream PARP cleavage (Supplementary
Figure 1d). Still, the chemo-resistance reported in the
LNCaP_USP2aWT cells is specifically dependent on the
catalytic activity of the protein, as the drug response observed
in the USP2aMUT cells resembles what reported in the
LNCaP_EV cells (Supplementary Figure 1e).
USP2a modulates the cell redox state. Cisplatin is known
to trigger apoptosis through oxidative stress, p38 kinase
activation and mitochondria impairment in different cancer
cell types, including prostate.34–36 We thus evaluated the
generation of ROS and the depolarization of mitochondria
membrane potential in iPrEC cells, following CDDP
administration. Cytofluorimetric analysis revealed that the
susceptibility of epithelial prostate cells to CDDP proceeds
via a dose-dependent ROS generation and DC depolariza-
tion (Figure 2a), accompanied by activation of p38 through
phosphorylation and caspase-3 cleavage (Figure 2b).
CDDP-induced oxidative stress appears to be an upstream
molecular event, as specific inhibition of ROS generation by
NAC (N-acetyl-cysteine) pre-treatment (Figure 2c) reduces
p38 phosphorylation, mitochondria depolarization and
downstream apoptosis, as evidenced by decreased PARP
cleavage and subG1 percentage (Figure 2d). However, as
NAC pre-loading does not completely abolish p38 activation
and PARP cleavage at the CDDP concentration of 5 mg/ml
(Figures 2c and d), it suggests that the drug-induced
apoptosis can involve alternative pathways at the higher
doses. As detailed in Supplementary Figure 2, only when
administered in combination with the specific p38 inhibitor
(SB202190), NAC interferes with the caspase-3 and PARP
activation (Supplementary Figure 2a) and reduces cell death
(Supplementary Figure 2b), suggesting the occurrence of a
double lane of cellular mediators (both ROS and p38) to
death (Supplementary Figure 2c).
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Figure 1 USP2a triggers chemo-resistance in prostate epithelial cells. Evaluation of (a) USP2a expression and (b–d) of the apoptotic response carried out by western blot
of cleaved PARP (cPARP) and cytofluorimetric assay of the subG1 percentage in the indicated iPrEC cells, following treatment with CDDP, DTX and Doxo
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Interestingly, when overexpressed, USP2aWT displays an
antioxidant effect. Its expression reduces the CDDP-
generated ROS and protects prostate cells from drug-induced
DC impairment at both the doses administered (Figure 2e).
If catalytically inactive, USP2a does not modify the iPrEC
sensitivity to CDDP-triggered oxidative stress and mitochondria
dysfunction, the iPrEC-USP2aMUT profile being comparable
to control cells (Figure 2f). Still, the ROS-scavenging
ability driven by USP2aWT in response to CDDP is able to
inhibit downstream p38 phosphorylation and caspase-3
cleavage if compared with mutant protein (Figure 2g). No
difference in p38 phosphorylation has been reported between
mutant and empty vector cells in response to drug (data not
shown).
Also in response to Doxo and DTX, iPrEC cells display an
increased ROS generation, which is actively scavenged by
NAC pre-exposure (Supplementary Figure 3a). Interestingly,
NAC treatment abolishes Doxo-induced citotoxicity, whereas
it only partially interferes with the apoptotic cascade initiated
by DTX (Supplementary Figure 3b). As USP2aWT scavenges
drug-induced ROS species, as much as NAC pre-treatment
(Supplementary Figure 3c), but also significantly impairs
apoptotic response to DTX (Figure 1c), it suggests that the
USP2a-dependent chemo-resistance to taxanes proceeds via
multiple pathways and that its antioxidant function is just one
of the involved mechanism.
To further characterize the antioxidant function, USP2aWT
overexpression was tested in response to direct H2O2
exposure in iPrEC cells (Figure 3). As hypothesized, it
protects from H2O2-induced ROS in a time-dependent
manner (Figure 3a), the M1-gated cells percentage
(ROS-positive cells) being significantly reduced in USP2aWT
compared with USP2aMUT and empty vector cells, at both 1
and 6 h post treatment. By extending the time-window of the
analysis up to 12 h, USP2aWT cells are further demonstrated
to be protected from the H2O2-driven cytotoxic effect
(Figure 3b). As the main master regulator of cellular redox
homeostasis is the glutathione (GSH), we measured the
intracellular GSH content in iPrEC transfectants (Figure 3c)
and showed that USP2aWT buffers the H2O2-induced
oxidative stress by implementing the GSH pool in prostate
cells. In iPrEC-USP2aWT cells, GSH content is indeed
increased by almost 30% if compared with USP2aMUT
(Figure 3c) and empty vector control clone.
In support of these findings, deregulated USP2a
expression is able to significantly affect GSH concentration
also in the LNCaP experimental model (Supplementary
Figure 4a).
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Figure 2 USP2a has an antioxidant effect in response to CDDP. Evaluation of (a) ROS production andDC depolarization, and (b) p38 kinase phosphorylation (Pp38) and
caspase-3 activation, carried out in iPrEC cells, following CDDP exposure. Upon NAC pre-treatment, iPrEC cells have been characterized in response to CDDP in terms of
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(g) p38 and casapse-3 activation has been further carried out in iPrEC_USP2aWT (W) and iPrEC_USP2aMUT (M) cells, respectively, following CDDP exposure
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miR-dependent c-Myc regulation is involved in the
USP2a antioxidant ability. In search of a molecular effector
underlying the USP2a antioxidant ability, we evaluated the
involvement of c-Myc oncoprotein in the USP2a chemo-
protection, as it is a well-known drug resistance factor in
cancer,34,37,38 and is upregulated by USP2a via miR-34b/c
impairment in prostate cells.19
To this purpose, we first verified whether c-Myc expression
was induced by drug treatment in the USP2aWT and control
LNCaP cells (Figures 4a and b). In response to CDDP, LNCaP
cells attempt to react to drug-induced damage by increasing
c-Myc protein as early as 2 h after drug administration
(Figure 4b). c-Myc expression level is maintained for the
following 12 h, returning progressively to basal level by 24 h.
Interestingly, activation of p38 is inversely correlated to c-Myc
induction, the kinase being progressively phosphorylated with
the disappearance of c-Myc. Through upregulation of basal
c-Myc level (Figure 4a), USP2aWT confers resistance to
CDDP by enabling LNCaP cells to quickly respond to drug
damage. In fact, c-Myc protein expression is kept higher than
in empty vector transfectants, and no phosphorylation of p38
kinase can be triggered by drug in USP2aWT cells. The ability
of c-Myc to specifically protect cells from CDDP-induced
damage was confirmed by evaluating the drug response
in c-Myc-overexpressing prostate cancer cells. c-Myc
stimulation in LNCaP cells (Supplementary Figure 5a) abro-
gates CDDP-induced p38 phosphorylation (Supplementary
Figure 5b), reduces the apoptotic subG1 percentage in a
dose-dependent manner, even more efficiently than what
reported for USP2aWT overexpression (Supplementary Figure 5c),
and inhibits PARP cleavage (Supplementary Figure 5d). In
accordance, c-Myc interference in LNCaP_USP2aWT-
overexpressing cells partially reverts CDDP resistance.
As shown in Figure 4c, siMyc stimulates apoptosis in
response to cisplatin and leads to a concomitant appearance
of cleaved PARP at the lowest dose reported (Figure 4d),
although the drug susceptibility is never completely restored
to parental level.
c-Myc-driven protection from CDDP in USP2aWT cells
proceeds via GSH modulation. As reported in Figure 4e,
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siMyc depletes GSH content in the LNCaP_USP2aWT,
down to basal levels, thus interfering with the ROS
scavenging properties gained with USP2aWT overexpression
(Figure 4f). We previously demonstrated that c-Myc tran-
scription factor regulates the g-glutamyl-cysteine synthe-
tase (g-GCS), the rate-limiting enzyme catalyzing GSH
biosynthesis, by directly binding and activating the
promoters of both heavy (g-GCSH) and light (g-GCSL)
subunits.34,39 We therefore verified whether the GSH
modulation may proceed via a Myc-dependent regulation
of g-GCS expression in our USP2aWT prostate experimental
model. As reported in Supplementary Figure 6, USP2aWT
stimulates both g-GCS subunit expression in LNCaP cells,
in terms of mRNA, protein, and enzyme activity rise.
Consistently, siUSP2a-LNCaP cells are characterized by a
significant decrease in g-GCS activity (Supplementary
Figure 4b). This expression control is clearly USP2aWT-
specific, as both LNCaP_USP2aMUT and iPrEC_USP2aMUT
cells resemble what is observed in the empty vector clones
(Supplementary Figure 4b).
As hypothesized, c-Myc is the master regulator in the
USP2a-driven g-GCS regulation, as c-Myc silencing reverts
the expression and activity stimulation elicited by USP2aWT
(Supplementary Figures 6a–d).
We also demonstrated that c-Myc regulation by USP2a
occurs via miR-34b/c inhibition.19 We next moved to verify
whether GSH-dependent drug resistance to pro-oxidant
agents might also be reverted by the synthetic miR molecules.
To this end, LNCaP_USP2aWT cells have been preloaded
with either control or mimic 34b and 34c molecules before
undergoing drug treatment (Figure 5). As expected, both
miR-34b and miR-34c are able to reduce c-Myc protein
expression in prostate cells, whereas the control mimic does
not modify its level (Figure 5a). Interestingly, exogenous
miR-34b/c loading does not completely counteract c-Myc
induction upon CDDP treatment (Supplementary Figure 7),
suggesting the occurrence of alternative pathways controlling
Myc induction and stabilization by the drug-induced stress.
The glutathione pool undergoes a significant depletion upon
mimic miR addition (Figure 5b), and it is in turn responsible
for the marked reduced ROS scavenging ability observed
in CDDP-treated LNCaP_USP2aWT cells (Figure 5d).
miR-dependent GSH depletion is triggered by the impairment
of the g-GCS expression and enzyme activity (Figure 5c) in the
USP2aWT cells. On the basis of an in silico prediction, carried
out by interrogating the public databases and algorithms
available on the web (Sanger miRbase, PicTar, Target Scan,
miRanda, DIANA miRGen, miRNA Map),31 we excluded that
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the inhibition of g-GCS expression in our experimental model
is due to a direct targeting by miR-34b/c (data not shown).
The combination of USP2aWT and control mimic molecule
still protects cells from CDDP-induced apoptosis, if compared
with control clone, as evidenced by the percentage of cells
exposing the early Annexin V marker (Figure 5d), and PARP
cleavage (Figure 5e). In contrast, pre-treatment with either
miR-34b or miR-34c makes USP2aWT cells unable to trigger
drug resistance. Actually, miR analogs per se are responsible
for activating a very small amount of apoptosis in proliferating
USP2aWT cells, as demonstrated by the slight increase in
Annexin Vþ /propidium iodide (PI) percentage and by the
faint appearance of PARP cleavage in the untreated cells
(Figures 5d and e). Moreover, each specific miR analog
abolishes the protective effect elicited by USP2aWT in
response to CDDP, the percentage of Annexin Vþ /PI cells
being comparable to vector-transfected LNCaP cells
(Figure 5d). Analysis of PARP cleavage confirms that both
miR-34b and miR-34c are able to revert cisplatin resistance,
although at different extent, the relative protein amount being
slightly different from parental CDDP-treated cells (Figure 5e).
Discussion
Despite the critical role of the ubiquitin–proteasome pathway
in the regulation of cellular processes and cancer transforma-
tion,3,40,41 surprisingly little is known about the function
specificity of individual DUB enzymes. We have recently
identified a novel molecular pathway of oncogenic regulation
driven by the USP2a deubiquitinating enzyme through its
ability to recruit specific miRNAs in prostate cells.19 Here
we demonstrate that USP2a also triggers prostate
chemo-resistance by acting as an antioxidant molecule via
the miR-34-mediated Myc and GSH stimulation. To our
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knowledge, this is the first report disclosing the cooperation
between a DUB enzyme and the miR regulatory machinery
specifically in response to oxidative stress.
We here report that the ectopic overexpression of USP2aWT
drives chemo-resistance in both iPrEC and prostate cancer
LNCaP cells, in accordance to that previously suggested in
prostate histotype by our group.11 This oncogenic property
also applies to other cancer cell lines, as seen in bladder
cancer and in testicular embryonal carcinoma cells, where
USP2a deregulation affects response to cisplatin.14,42 These
findings are suggestive of a possible clinical application of
USP2a inhibitors to cisplatin-resistant patient population to
improve clinical benefit.
Interestingly, in our prostate experimental model, USP2a is
able to specifically impair the death response to the pro-
oxidant agents, such as CDDP and Doxo, and to microtubules
polymerization inhibitors, such as DTX and paclitaxel.11 In
accordance to our findings, siUSP2a bladder cancer cells are
reported to display a higher apoptotic rate in response to
CDDP and nocodazole, an antineoplastic agent specifically
interfering with the polymerization of microtubules.42
This USP2a function can be attributable to its deubiquitinating
activity, as the response elicited by the catalytically inactive
mutant (C276A and H549R) resembles that reported in
control cells. Thus, USP2a might specifically address the
chemo-response by deubiquitinating and stabilizing different
proteins according to the nature of the stressor. Besides, its
action may depend on the cellular balance with other death-
regulating effectors. This is particularly evident following the
recent publication by Mahul-Mellier on Hela and MCF7 breast
cancer cells, where downregulation of USP2a by siRNA
promotes NF-kB activation and protects cells against
TNF-induced cell death, as a consequence of the impairment
of the USP2a-TRAF protein ratio.43,44
Cisplatin has been extensively used in prostate cancer
therapy, and, at molecular level, it is known to trigger
apoptosis through mitochondria-mediated oxidative stress.35,36
The cytotoxicity of anthracyclines is also associated with the
generation of reactive oxygen species (ROS) and reactive
nitrogen species (RNS). Besides, Doxo can bind to the
DNA and uncoil the double-stranded helix with generation of
free radicals and DNA damage.45,46 Interestingly, although
taxanes are mainly mitotic inhibitors, through disruption of
microtubule function, recent data on mitochondrial ROS
formation showed that they can display direct mitochondrial
effect, induce mitochondrial permeability transition and ROS
formation.29–31
We here demonstrate that ROS generation is a key
upstream event responsible for CDDP cytotoxicity in prostate,
and that USP2a behaves as a ROS scavenging molecule,
even if p38 phosphorylation may occur independently of
oxidative stress at higher doses. Both Doxo and DTX also
elicit ROS generation, that is efficiently scavenged by
USP2aWT, although, according to our data, chemo-resistance
to taxanes proceeds via multiple pathways, and USP2a
antioxidant function is just one of the involved mechanism. On
the basis of what already published, resistance to taxanes
might be explained in terms of the proteins stabilized by
USP2a-deubiquitinating function, especially those involved in
apoptosis, such as FASN, Mdm2, MdmX and AIF, or by the
multiple miR molecules regulated in the prostate experimental
model. Future intensive experiments are required to exhaus-
tively address these issues.
Pro-oxidant chemo-therapy appears particularly efficient in
prostate cells. Over the last decade, epidemiological, experi-
mental and clinical studies have in fact implicated oxidative
stress in the development and progression of prostate
cancer.47 A possible explanation identifies in the oxidative
stress the key factor responsible for the activation of androgen
receptor signaling and for the pro-survival and antiapoptotic
effects in response to androgen-deprivation therapy, as well
as to cytotoxic and tumor-suppressive interventions.48
In the light of these evidences, it is comprehensible that the
impact of USP2a overexpression in a prostate lesion, as, in
response to CDDP, it displays an antioxidant effect. To our
knowledge, this is the first experimental evidence demonstrat-
ing a ROS-scavenging role for USP2a and, more important,
identifying in the intracellular GSH neo-synthesis the possible
mediator of this protective effect. This finding is surprisingly
in accordance to what has recently been published by
Selvendiran et al.49 They report that the synthetic compound
HO-3867, known for its potent antioxidant activity, exhibits
anticancer effects in many histotypes, including the breast,
colon, head and neck, liver, lung, ovarian and prostate, by
downregulating USP2a to ultimately trigger apoptosis.49
There is an emerging evidence supporting the role of
miRNAs in modulating sensitivity to anticancer therapy, and
miR-34a and miR-34b/c family in particular has been
associated to prostate cancer survival and drug sensitivity.50–53
We recently demonstrated that USP2a switches on
Myc expression via miR-34b/c regulation.19 The ability to
affect c-Myc level by miR has its functional relevance in the
regulation of apoptosis and response to chemotherapy. c-Myc
is in fact known to be a drug resistance factor.34,37,38 Different
c-Myc-targeted antisense therapies have been so far
developed and tested as reliable strategies to improve
chemotherapy in solid tumors, strongly identifying in c-Myc a
key factor of drug resistance and stress response. In prostate,
c-myc is often amplified in advanced cancer specimens54, so
that targeted inhibition of its overexpression has been
demonstrated as a promising therapeutic strategy for clinical
management of prostate cancer.55 Moreover, therapeutic use
of c-myc antisense renders hormone-refractory prostate
cancers responsive to chemotherapy in the preclinical
model.56
Here we demonstrate that USP2aWT confers drug resis-
tance by upregulating c-Myc expression and by implementing
the GSH content. This is directly due to the ability of c-Myc
transcription factor to stimulate the expression of g-GCS, the
rate-limiting enzyme catalyzing the GSH biosynthesis.
Moreover, miR-34b/c-mediated c-Myc stimulation is set
upstream the GSH neo-synthesis, as both miR mimic
administration and Myc silencing in LNCaP-USP2aWT cells
are responsible for g-GCS inhibition and consequent GSH
depletion, with further chemo-sensitization to pro-oxidant
agents. This is consistent with our previously reported data
demonstrating a direct antioxidant role of c-Myc through
regulation of glutathione synthesis,34,39 also corroborated by
Gao et al who disclosed c-Myc involvement in energy and
reactive oxygen species homeostasis.57 These data might
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strengthen the hypothesis of a therapeutic approach in
USP2a-overexpressing prostate lesions based on the combi-
nation of conventional chemotherapy with either miR synthetic
drugs or siMyc.
On the basis of our data, we propose a molecular model
where USP2a is the upstream master regulator, driving the
response to ROS-generating drugs via miR-34b/c-Myc-GSH
in prostate cells (Figure 6). In the scheme, we also highlight
those miRNAs that we previously identified as USP2a targets,
such as let-7, miR-98 and miR-17-5p.19 According to
published evidence, they are known to interfere with the
expression of specific targets (BIM, IL-6/STAT3, HMGA2 and
Bcl-2), specifically involved in the apoptotic response to
pro-oxidant agents and antineoplastic drugs.58–60 In our
hypothesis, prostate chemo-resistance might be regulated
by USP2a through multiple pathways, according to the dose
and the nature of the stressor. Further studies in this direction
will help in better defining the involvement of each specific
molecular mediator in the complex web of interaction woven
by USP2a in prostate cancer cells.
Materials and Methods
Chemicals, antibodies and plasmids. Clinical-grade cisplatin and
doxorubicin were obtained from Pharmacia (Milan, Italy). Docetaxel was
purchased from Sigma (Sigma-Aldrich, St. Louis, MO, USA) and Glaxo Wellcome
(Verona, Italy), respectively. Drug dilutions were freshly prepared before each
experiment.
NAC, H2O2 (30% w/w) and PI were from Sigma. DHE (dihydroethidium), JC-1
(50,6,60-tetrachloro-1,10,3,30-tetraethylbenzimidazolylcarbocyanine iodide) and the
Annexin V-FITC versus PI kit (Vibrant apoptosis assay, V-13242) were purchased
from Molecular Probes (Life Technologies, Grand Island, NY, USA).
For western blot analysis, the following primary antibodies have been used:
anti-USP2a (N-term and C-term, Abgent, San Diego, CA, USA), anti-c-Myc (clone
9E10, Santa Cruz, CA, USA), anti-procaspase-3 and cleaved caspase-3 (Upstate
Biotechnology, New York, NY), anti-cleaved PARP (cPARP, Roche Applied
Sciences, Indianapolis, IN, USA), anti-p38 and phospoho-p38 (Cell Signaling
Technology, Danvers, MA, USA), anti-gGCSH and anti-gGCSL (Santa Cruz), anti-
GAPDH (6C5, Santa Cruz) and anti-beta actin (AC-74, Sigma).
Overexpression experiments have been performed by transfecting cells with
pCDNA3 empty vector (Invitrogen, Life Technologies), pCDNA3-USP2aWT
(pUSP2aWT) and pCDNA3-USP2aMUT (pUSP2aMUT), as previously described.11,19
Silencing oligonucleotides (siRNA) for knockdown experiments have been
purchased from MWG (Huntsville, AL, USA), as previously detailed.19 Synthetic
(Mimic) miRNA sequences (control, miR-34b and 34c) were purchased
from Dharmacon (Thermo Scientific, Pittsburgh PA, USA). Lyophilized
molecules have been dissolved in diethylpyrocarbonate (DEPC) water, stocked
and freshly diluted before experiments, according to the manufacturer’s
instructions.
Cell culture and transfection. Empty vector (Vector), wild-type
(USP2aWT) and mutant (USP2aMUT) stable clones (previously established by
infecting immortalized androgen receptor-expressing prostate epithelial cells
(iPrEC)11,19 were grown in specific PrEBM medium (Cambrex, East Rutherford,
NJ, USA) and selected in 1.6mg/ml puromycin. Human prostate adenocarcinoma
LNCaP cells were obtained from the American Type Culture Collection (ATCC,
Manassas, VA, USA) and grown in RPMI-1640 medium (Invitrogen) containing
10% fetal bovine serum (GIBCO-Invitrogen) and 1% penicillin-streptomycin
(Invitrogen).
Transient transfection experiments were carried out by seeding cells in 60-mm
Petri dishes in complete medium (2 105 cells/plate). Transfection was performed
24 h after plating using Lipofectamine 2000 reagent (Invitrogen) in Optimem
medium (Invitrogen) for siRNA oligonucleotides (100–500 nM) and synthetiC miR
molecules (10 nM), and by JetPei reagent (PloyPlus-Transfection, New York, NY,
USA) in complete medium for expression vectors (0.5–5 mg). Evaluation of protein,
mRNA and miRNA expression levels was performed by harvesting cells at 24 h
intervals (24–120 h) after transfection.
Treatment with antineoplastic agents and H2O2. For drug treatment,
cells were seeded in 60-mm Petri dishes at a density of 2 105 cells/plate. After
24 h, cells were exposed for 2–24 h to different doses of CDDP (ranging from 0.5
to 10mg/ml), DTX (ranging from 1 to 25 nM) and Doxo (ranging from 0.1 to 1mM).
In the experiments with NAC antioxidant, cells were incubated with 5 mM NAC
(dose with no toxic effect on cell survival) 6 h before drug administration.
In the experiments with H2O2, iPrEC cells (2 105 cells/plate) were incubated
with 100mM of the pro-oxidant agent for 1–12 h and immediately analyzed for
apoptosis, GSH content and ROS generation.
miR-17-5p
BIM
USP2a
miR-34b/c miR-98let-7c
c-Myc HMGA2
Bcl-2-GCS
GSH
Oxidative stress
Cisplatin
H2O2
Pro-oxidant agents
Apoptosis and
chemosensitivity
IL-6/STAT3
Figure 6 USP2a-activated pathways in response to oxidative stress. The schematized molecular model describes the multiple miRNA-target connections triggered by
USP2a overexpression in prostate cells, in response to pro-oxidant agents. Solid lines represent that demonstrated by our present and recently published data.19 Dotted lines
suggest further potential USP2a-miRNA-target cross-talks, underlying the antioxidant and chemo-protective function elicited by USP2a in prostate
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Western blot. Cell lysis was performed on ice for 30 min in RIPA buffer (50 mM
Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 0.25% sodium deoxycholate, 1 mM
EDTA) supplemented with phosphatase inhibitors (1 mM PMSF, 1mg/ml aprotinin,
leupeptin, pepstatin). Equal amounts of total protein extracts (20–80mg) were
resolved by 10%, 12% or 15% denaturing SDS polyacrylamide gel electrophoresis
(SDS–PAGE) and transferred for 4 h to the polyvinylidene difluoride membrane.
Membranes were blocked in 5% milk-PBS-0.05% Tween 20 for 1 h and incubated
overnight with the specific primary antibodies. Secondary antibodies were
horseradish peroxidase-conjugated (Santa Cruz), and ECL reagent (Amersham,
GE Healthcare, Piscataway, NJ, USA) was employed for chemo-luminescence
detection.
GSH Determination. Intracellular GSH content was measured as previously
described19, using a colorimetric assay (Bioxytech GSH-400; Oxis International
Inc., Beverly Hills, CA, USA), according to the manufacturer’s instruction.
cGCS enzyme activity. Enzymatic activity was evaluated by using a coupled
assay with pyruvate kinase and lactate dehydrogenase and assaying the rate of
decrease in absorbance at 340 nm at 37 1C. Enzyme activity was expressed as
mmol of NADH oxidized per minute (U) per mg protein.34
Flow cytometric evaluation of apoptosis. Apoptosis was detected by
both PI staining of 80% ethanol-fixed cells and Annexin V-FITC versus PI assay
performed in fresh cells, as previously described.19
Briefly, ethanol-fixed cells were washed in phosphate buffered saline (PBS),
stained in a solution (containing RNase A (50 mg/ml, Sigma), Triton 0.1%,
EDTA (0.1 mM, Sigma) and PI (50 mg/ml) in PBS) and incubated in the dark for at
least 30 min. SubG1 percentage has been determined by analyzing DNA content
using the flow cytometer (Beckton and Dickinson, Frankin Lakes, NJ, USA).
For the Annexin assay, adherent cells were harvested, suspended in the
annexin-binding buffer (about 1 106 cells/ml) and incubated with the Annexin
V-FITC and PI for 15 min, at room temperature in the dark, then immediately
analyzed using flow cytometry. These data are presented as bi-parametric dot
plots showing the annexin V-FITC green fluorescence versus the PI red
fluorescence. Analysis of cell death was performed from 0 to 96 h after the end of
each drug treatment.
Assessment of the mitochondrial membrane potential. DC was
assayed by staining cells with the JC-1 probe, a cationic dye that exhibits
mitochondria potential-dependent accumulation, without being affected by
the plasmalemma potential. JC-1 accumulates in the cytoplasm, where it
produces green fluorescence and forms red fluorescent J-aggregates in the
mitochondria. Mitochondria depolarization is indicated by a decrease in the
red/green fluorescence intensity ratio. Adherent cells (about 5 105) were first
assayed for viability and then loaded with 10 mM JC-1 in complete medium, for
30 min at 37 1C in the dark. After incubation, cells were washed twice and
suspended in PBS, then immediately analyzed using flow cytometry (Beckton
and Dickinson). These data are presented as bi-parametric panels with the
green J-monomers fluorescence plotted versus the red J-aggregates
fluorescence. Analysis of DC was performed from 0 to 72 h following the
end of drug administration.
Evaluation of the reactive oxygen species. The evaluation of ROS
production was performed as previously described.19 Briefly, adherent cells (about
5 105) were first assayed for viability and then incubated with 4 mM DHE for
45 min at 37 1C in PBS. After incubation, cells were immediately analyzed using
flow cytometry. These data are presented as both mono-parametric histograms or
bi-parametric panels with the red DHE fluorescence intensity plotted versus the
forward scatter. Analysis of ROS generation was performed from 0 to 72 h
following the end of each drug treatment.
Statistical analysis. All data are presented as mean±S.D., calculated in
X three replicates. Statistical analyses were performed using an unpaired two-
tailed t test using SPSS Software Version One. P-values o0.05 were taken as
statistically significant.
Conflict of Interest
The authors declare no conflict of interest.
1. Bernards R. A genomic and functional inventory of deubiquitinating enzymes. Cell 2005;
123: 773–786.
2. Salmena L, Pandolfi PP. Changing venues for tumour suppression: balancing destruction
and localization by monoubiquitylation. Nat Rev Cancer 2007; 7: 409–413.
3. Yang Y, Kitagaki J, Wang H, Hou DX, Perantoni AO. Targeting the ubiquitin-proteasome
system for cancer therapy. Cancer Sci 2009; 100: 24–28.
4. Ruschak AM, Slassi M, Kay LE, Schimmer AD. Novel proteasome inhibitors to overcome
bortezomib resistance. J Natl Cancer Inst 2011; 103: 1007–1017.
5. Inuzuka H, Fukushima H, Shaik S, Liu P, Lau AW, Wei W. Mcl-1 ubiquitination and
destruction. Oncotarget 2011; 2: 239–244.
6. Neznanov N, Komarov AP, Neznanova L, Stanhope-Baker P, Gudkov AV. Proteotoxic
stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor
effect of the proteasome inhibitor bortezomib. Oncotarget 2011; 2: 209–221.
7. Donna LD, Lagadec C, Pajonk F. Radioresistance of prostate cancer cells with low
proteasome activity. Prostate 2011; 72: 868–874.
8. Jandial DD, Farshchi-Heydari S, Larson CA, Elliott GI, Wrasidlo WJ, Howell SB. Enhanced
delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of
bortezomib on the human copper transporter 1. Clin Cancer Res 2009; 15: 553–560.
9. Liu L, Yang C, Herzog C, Seth R, Kaushal GP. Proteasome inhibitors prevent cisplatin-
induced mitochondrial release of apoptosis-inducing factor and markedly ameliorate
cisplatin nephrotoxicity. Biochem Pharmacol 2010; 79: 137–146.
10. Stringer DK, Piper RC. Terminating protein ubiquitination: Hasta la vista, ubiquitin. Cell
Cycle 2011; 10: 3067–3071.
11. Priolo C, Tang D, Brahamandan M, Benassi B, Sicinska E, Ogino S et al. The isopeptidase
USP2a protects human prostate cancer from apoptosis. Cancer Res 2006; 66: 8625–8632.
12. Graner E, Tang D, Rossi S, Baron A, Migita T, Weinstein LJ et al. The isopeptidase USP2a
regulates the stability of fatty acid synthase in prostate cancer. Cancer Cell 2004; 5:
253–261.
13. Stevenson LF, Sparks A, Allende-Vega N, Xirodimas DP, Lane DP, Saville MK.
The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2.
EMBO J 2007; 26: 976–986.
14. Allende-Vega N, Sparks A, Lane DP, Saville MK. MdmX is a substrate for the
deubiquitinating enzyme USP2a. Oncogene 2010; 29: 432–441.
15. Oh KH, Yang SW, Park JM, Seol JH, Iemura S, Natsume T et al. Control of AIF-mediated
cell death by antagonistic functions of CHIP ubiquitin E3 ligase and USP2 deubiquitinating
enzyme. Cell Death Differ 2011; 18: 1326–1336.
16. Shi Y, Solomon LR, Pereda-Lopez A, Giranda VL, Luo Y, Johnson EF et al.
The deubiquitinase USP2A regulates the stability of aurora-A. J Biol Chem 2011; 286:
38960–38968.
17. Shan J, Zhao W, Gu W. Suppression of cancer cell growth by promoting cyclin D1
degradation. Mol Cell 2009; 36: 469–476.
18. Liu Z, Zanata SM, Kim J, Peterson MA, Di Vizio D, Chirieac LR et al. The ubiquitin-specific
protease USP2a prevents endocytosis-mediated EGFR degradation. Oncogene 2012; 32:
1660–1669.
19. Benassi B, Flavin R, Marchionni L, Zanata S, Pan Y, Chowdhury D et al. MYC is activated
by USP2a-mediated modulation of microRNAs in prostate cancer. Cancer Discov 2012; 2:
236–247.
20. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F et al. A microRNA expression
signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA
2006; 103: 2257–2261.
21. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T. MicroRNA
expression profiling in prostate cancer. Cancer Res 2007; 67: 6130–6135.
22. Ozen M, Creighton CJ, Ozdemir M, Ittmann M. Widespread deregulation of microRNA
expression in human prostate cancer. Oncogene 2008; 27: 1788–1793.
23. Hummel R, Hussey DJ, Haier J. MicroRNAs: predictors and modifiers of chemo- and
radiotherapy in different tumour types. Eur J Cancer 2010; 46: 298–311.
24. Fujita Y, Kojima K, Ohhashi R, Hamada N, Nozawa Y, Kitamoto A et al. MiR-148a
attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3
cells by regulating MSK1 expression. J Biol Chem 2010; 285: 19076–19084.
25. Xu B, Niu X, Zhang X, Tao J, Wu D, Wang Z et al. miR-143 decreases prostate cancer cells
proliferation and migration and enhances their sensitivity to docetaxel through suppression
of KRAS. Mol Cell Biochem 2011; 350: 207–213.
26. Fujita Y, Kojima K, Hamada N, Ohhashi R, Akao Y, Nozawa Y et al. Effects of miR-34a on
cell growth and chemoresistance in prostate cancer PC3 cells. Biochem Biophys Res
Commun 2008; 377: 114–119.
27. Rokhlin OW, Scheinker VS, Taghiyev AF, Bumcrot D, Glover RA, Cohen MB.
MicroRNA-34 mediates AR-dependent p53-induced apoptosis in prostate cancer.
Cancer Biol Ther 2008; 7: 1288–1296.
28. Kojima K, Fujita Y, Nozawa Y, Deguchi T, Ito M. MiR-34a attenuates paclitaxel-resistance
of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms.
Prostate 2010; 70: 1501–1512.
29. Varbiro G, Veres B, Gallyas F Jr, Sumegi B. Direct effect of taxol on free radical formation
and mitochondrial permeability transition. Free Radical Biol Med 2001; 31: 548–558.
30. Ozben T. Oxidative stress and apoptosis: impact on cancer therapy. Journal of
Pharmacological Science 2007; 96: 2181–2196.
31. Mediavilla-Varela M, Pacheco FJ, Almaguel F, Perez J, Sahakian E, Daniels TR et al.
Docetaxel-induced prostate cancer cell death involves concomitant activation of caspase
USP2a-dependent GSH modulation
B Benassi et al
9
Cell Death and Disease
and lysosomal pathways and is attenuated by LEDGF/p75. Molecular Cancer 2009; 28:
68–74.
32. Shah N, Dizon DS. New-generation platinum agents for solid tumors. Future Oncol 2009; 5:
33–42.
33. Itoh T, Terazawa R, Kojima K, Nakane K, Deguchi T, Ando M et al. Cisplatin induces
production of reactive oxygen species via NADPH oxidase activation in human prostate
cancer cells. Free Radic Res 2011; 45: 1033–1039.
34. Benassi B, Fanciulli M, Fiorentino F, Porrello A, Chiorino G, Loda M et al. c-Myc
phosphorylation is required for cellular response to oxidative stress. Mol Cell 2006; 21:
509–519.
35. Schweyer S, Soruri A, Heintze A, Radzun HJ, Fayyazi A. The role of reactive oxygen
species in cisplatin-induced apoptosis in human malignant testicular germ cell lines. Int J
Oncol 2004; 25: 1671–1676.
36. Bragado P, Armesilla A, Silva A, Porras A. Apoptosis by cisplatin requires p53 mediated
p38alpha MAPK activation through ROS generation. Apoptosis 2007; 12: 1733–1742.
37. el-Deiry WS. Role of oncogenes in resistance and killing by cancer therapeutic agents. Curr
Opin Oncol 1997; 9: 79–87.
38. Hattinger CM, Stoico G, Michelacci F, Pasello M, Scionti I, Remondini D et al. Mechanisms
of gene amplification and evidence of coamplification in drug-resistant human
osteosarcoma cell lines. Genes Chromosomes Cancer 2009; 48: 289–309.
39. Benassi B, Zupi G, Biroccio A. Gamma-glutamylcysteine synthetase mediates the
c-Myc-dependent response to antineoplastic agents in melanoma cells. Mol Pharm 2007;
72: 1015–1023.
40. Yang Y, Li CC, Weissman AM. Regulating the p53 system through ubiquitination.
Oncogene 2004; 23: 2096–2106.
41. Ruffner H, Joazeiro CA, Hemmati D, Hunter T, Verma IM. Cancer-predisposing mutations
within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection
from radiation hypersensitivity. Proc Natl Acad Sci USA 2001; 98: 5134–5139.
42. Kim J, Kim WJ, Liu Z, Loda M, Freeman MR. The ubiquitin-specific protease USP2a
enhances tumor progression by targeting cyclin A1 in bladder cancer. Cell Cycle 2012; 11:
1123–1130.
43. Mahul-Mellier AL, Pazarentzos E, Datler C, Iwasawa R, AbuAli G, Lin B, Grimm S.
De-ubiquitinating protease USP2a targets RIP1 and TRAF2 to mediate cell death by TNF.
Cell Death Differ 2012; 19: 891–899.
44. Mahul-Mellier AL, Datler C, Pazarentzos E, Lin B, Chaisaklert W, Abuali G, Grimm S.
De-ubiquitinating proteases USP2a and USP2c cause apoptosis by stabilising RIP1.
Biochim Biophys Acta 2012; 1823: 1353–1365.
45. Nicolson GL, Conklin KA. Reversing mitochondrial dysfunction, fatigue and the adverse
effects of chemotherapy of metastatic disease by molecular replacement therapy. Clin Exp
Metastasis 2008; 25: 161–169.
46. Pienia˛z˙ek A, Czepas J, Piasecka-Zelga J, Gwoz´dzin´ski K, Koceva-Chy"a A. Oxidative
stress induced in rat liver by anticancer drugs doxorubicin, paclitaxel and docetaxel. Adv
Med Sci 2013; 20: 24–31.
47. Battisti V, Maders LD, Bagatini MD, Reetz LG, Chiesa J, Battisti IE et al. Oxidative stress
and antioxidant status in prostate cancer patients: relation to Gleason score, treatment and
bone metastasis. Biomed Pharmacother 2011; 65: 516–524.
48. Shiota M, Yokomizo A, Naito S. Pro-survival and anti-apoptotic properties of androgen
receptor signaling by oxidative stress promote treatment resistance in prostate cancer.
Endocr Relat Cancer 2012; 19: R243–R253.
49. Selvendiran K, Ahmed S, Dayton A, Ravi Y, Kuppusamy ML, Bratasz A et al. HO-3867, a
synthetic compound, inhibits the migration and invasion of ovarian carcinoma cells through
downregulation of fatty acid synthase and focal adhesion kinase. Mol Cancer Res 2010; 8:
1188–1197.
50. Drayton RM. The role of microRNA in the response to cisplatin treatment. Biochem Soc
Trans 2012; 40: 821–825.
51. Blower PE, Chung JH, Verducci JS, Lin S, Park JK, Dai Z et al. MicroRNAs modulate the
chemosensitivity of tumor cells. Mol Cancer Ther 2008; 7: 1–9.
52. Weidhaas JB, Babar I, Nallur SM, Trang P, Roush S, Boehm M et al. MicroRNAs as
potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Res 2007; 67:
11111–11116.
53. Watahiki A, Wang Y, Morris J, Dennis K, O’Dwyer HM, Gleave M et al. MicroRNAs
associated with metastatic prostate cancer. PLoS One 2011; 6: e24950.
54. Jenkins RB, Qian J, Lieber MM, Bostwick DG. Detection of c-myc oncogene amplification
and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ
hybridization. Cancer Res 1997; 57: 524–531.
55. Iversen PL, Arora V, Acker AJ, Mason DH, Devi GR. Efficacy of antisense morpholino
oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety
study in humans. Clin Cancer Res 2003; 9: 2510–2519.
56. Leonetti C, Biroccio A, D’Angelo C, Semple SC, Scarsella M, Zupi G. Therapeutic
integration of c-myc and bcl-2 antisense molecules with docetaxel in a preclinical model of
hormone-refractory prostate cancer. Prostate 2007; 67: 1475–1485.
57. Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T et al. c-Myc suppression of miR-
23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature
2009; 458: 762–765.
58. Fontana L, Fiori ME, Albini S, Cifaldi L, Giovinazzi S, Forloni M et al. Antagomir-17-5p
abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS One
2008; 3: e2236.
59. Sugimura K, Miyata H, Tanaka K, Hamano R, Takahashi T, Kurokawa Y et al. Let-7
expression is a significant determinant of response to chemotherapy through the regulation
of IL-6/STAT3 pathway in esophageal squamous cell carcinoma. Clin Cancer Res 2012;
18: 5144–5153.
60. Hebert C, Norris K, Scheper MA, Nikitakis N, Sauk JJ. High mobility group A2 is
a target for miRNA-98 in head and neck squamous cell carcinoma. Mol Cancer
2007; 6: 5.
Cell Death and Disease is an open-access journal
published by Nature Publishing Group. This work is
licensed under a Creative Commons Attribution 3.0 Unported License.
To view a copy of this license, visit http://creativecommons.org/
licenses/by/3.0/
Supplementary Information accompanies this paper on Cell Death and Disease website (http://www.nature.com/cddis)
USP2a-dependent GSH modulation
B Benassi et al
10
Cell Death and Disease
